BioAffinity Technologies said on Wednesday that it will run a study of its CyPath Lung test for early lung cancer detection in collaboration with Brooke Army Medical Center (BAMC). CyPath Lung ...

The new funding will accelerate the development of a portable diagnostic platform to enhance care for bleeding disorders and critical care medicine.

NEW YORK – Irish diagnostic firm Trinity Biotech announced on Wednesday that it has entered into a $25 million standby equity purchase agreement with an affiliate of its financing partner Yorkville ...

The precision cancer diagnostics firm Epredia will distribute Mindpeak's AI-based image recognition solutions for clinical diagnostics, research, and pharma development.

The interferon-gamma release assay for latent tuberculosis infection is designed for use on Diasorin's automated, high-throughput Liaison XL platform.

Last week, readers were most interested in a story about a deal between QuidelOrtho and Shenzhen Lifotronic Technology covering immunoassays.

Labcorp said it will be using the company's FDA-cleared AISight Dx platform across its national network of anatomic pathology labs and hospital collaborations.

Among the major issues were tariff policies, reimbursement pathways for multi-cancer early detection tests, and reform of the ...

The test runs on the company's OneBreath platform and is designed to assess a patient's risk for postoperative pneumonia.

The cleared assays included point-of-care and home tests for infectious and chronic diseases and drugs of abuse.

The tests were developed by France's NG Biotech, which exclusively licensed their US distribution rights to Hardy.

The company reported revenue of $3.52 billion, up from $3.33 billion in Q4 2024 but below the Wall Street consensus estimate of $3.56 billion.